Last reviewed · How we verify
The Mentholatum Company — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Systane® Ultra | Systane® Ultra | marketed | Artificial tear lubricant | Ophthalmology | ||
| Rohto Dry-Aid® | Rohto Dry-Aid® | marketed | Artificial tear / ocular lubricant | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
- Chang Gung Memorial Hospital · 1 shared drug class
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · 1 shared drug class
- Massachusetts Eye and Ear Infirmary · 1 shared drug class
- Medical University of Vienna · 1 shared drug class
- Nguyen Viet Giap · 1 shared drug class
- ORA, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for The Mentholatum Company:
- The Mentholatum Company pipeline updates — RSS
- The Mentholatum Company pipeline updates — Atom
- The Mentholatum Company pipeline updates — JSON
Cite this brief
Drug Landscape (2026). The Mentholatum Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-mentholatum-company. Accessed 2026-05-16.